ReviewLung2020
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management.
Review in Lung, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.Biomolecules · 2024Pooled it
- Successful immunosuppressive treatment of hypersensitivity pneumonitis secondary to lycoperdonosis in a dog.Journal of veterinary internal medicine · 2026Article
- Nintedanib for progressive pulmonary fibrosis in real-world setting: an observational study comparing outcomes with an IPF cohort.BMC pulmonary medicine · 2026Observational
- Article
- Mir-155-5p targets TP53INP1 to promote proliferative phenotype in hypersensitivity pneumonitis lung fibroblasts.Non-coding RNA research · 2024Article
- Noninfectious Granulomatous Lung Disease: Radiological Findings and Differential Diagnosis.Journal of personalized medicine · 2024Review
- Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.Frontiers in medicine · 2024Review
- Real-Life Diagnostic Performance of the Hypersensitivity Pneumonitis Guidelines: A Multicenter Cohort Study.Diagnostics (Basel, Switzerland) · 2023Article
- The controversial effect of smoking and nicotine in SARS-CoV-2 infection.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Review
- Occupational hypersensitivity pneumonia.Tuberkuloz ve toraks · 2023Review
- The sirtuin family in health and disease.Signal transduction and targeted therapy · 2022Review
- Article
- The Lung Microbiome in Health, Hypersensitivity Pneumonitis, and Idiopathic Pulmonary Fibrosis: A Heavy Bacterial Burden to Bear.American journal of respiratory and critical care medicine · 2021Article
- LUNG Year in Review: 2020.Lung · 2021Article
- Therapeutic Effect of Neuraminidase-1-Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis.The Journal of pharmacology and experimental therapeutics · 2021Article
- Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.Frontiers in immunology · 2021Review
- Hypersensitivity Pneumonitis: Diagnostic and Therapeutic Challenges.Frontiers in medicine · 2021Review
- Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis.Journal of asthma and allergy · 2021Article
- Clinical characteristics and outcomes of hypersensitivity pneumonitis in South Korea.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrotic hypersensitivity pneumonitis is a complex interstitial lung disease that is not entirely understood. In its chronic and fibrotic form, hypersensitivity pneumonitis is one of the main mimickers of idiopathic pulmonary fibrosis (IPF). Distinguishing between these two conditions is challenging but is of particular clinical relevance. Two approved therapies are available for IPF, and a considerable number of clinical trials are now exploring newer pharmacological options. This impressive research effort is a consequence of new pathogenetic understanding, updated diagnostic criteria and a long history of pharmacological trials. Conversely, current knowledge gaps on pathogenesis of chronic hypersensitivity pneumonitis, coupled with lack of validated diagnostic criteria, make the management of this disease an unsolved clinical challenge. This also reflects the paucity of therapeutic clinical trials in this field. In this review, we describe the current evidence and the possible future options to approach this complex disease.
Indexed as
Identifiers
32415523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.